LASER:177Lu-PSMA-617 作为肾细胞癌系统治疗的 2 期试验
LASER 是一项单中心、开放标签、单臂 2 期试验,评估 177Lu-PSMA-617 在晚期 PSMA 阳性透明细胞肾细胞癌患者中的安全性和疗效。入组患者需接受过至少 1 种免疫检查点抑制剂和 1 种酪氨酸激酶抑制剂,且基线 68Ga-PSMA-11 PET/CT 显示多数病灶 PSMA 高摄取。主要终点为 RECIST 1.1 客观缓解率,采用两阶段设计,第一阶段 9 例,若至少 1 例客观缓解则继续入组至总共 24 例。
要点
- 靶点为 ccRCC 肿瘤新生血管表达的 PSMA,使用 177Lu-PSMA-617 进行放射性药物治疗。
- 入组要求既往接受过免疫检查点抑制剂和酪氨酸激酶抑制剂治疗,且基线 PSMA PET/CT 显示多数病灶摄取。
- 主要终点为 RECIST 1.1 客观缓解率,两阶段设计第一阶段 9 例需至少 1 例缓解才继续。
核心结论
- 该前瞻性试验旨在评估 177Lu-PSMA-617 在晚期 PSMA 阳性 ccRCC 患者中的安全性和初步疗效。
- 研究结果可能支持 PSMA 靶向放射性药物治疗作为标准系统治疗进展后患者的新治疗选择进行临床开发。
研究设计与样本
- 单中心、开放标签、单臂 2 期临床试验。
- 入组晚期 PSMA 阳性 ccRCC 患者,要求可测量病灶、既往接受过至少 1 种免疫检查点抑制剂和 1 种酪氨酸激酶抑制剂。
- 基线 68Ga-PSMA-11 PET/CT 需显示多数病灶 PSMA 高摄取。
- 患者每 6 周接受最多 6 个周期的 177Lu-PSMA-617 治疗。
- 采用两阶段设计:第一阶段入组 9 例,若至少 1 例客观缓解则继续入组 15 例,总计 24 例。
关键数值与推荐
- 主要终点为根据 RECIST 1.1 评估的客观缓解率。
- 次要终点包括安全性、无进展生存期和总生存期。
- 探索性目标包括影像生物标志物、循环游离 DNA 和基因组改变与临床结局的相关性。
临床怎么用
- 针对既往免疫检查点抑制剂和酪氨酸激酶抑制剂治疗后进展的 PSMA 阳性 ccRCC 患者,可考虑 177Lu-PSMA-617 治疗。
- 治疗前需通过 68Ga-PSMA-11 PET/CT 确认多数病灶 PSMA 高摄取。
- 每 6 周给药一次,最多 6 个周期,主要疗效评估采用 RECIST 1.1。
局限性
- 单中心、开放标签、单臂设计。
- 样本量计划为 24 例,第一阶段仅 9 例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal cell carcinoma is one of the most common malignancies in the United States, with clear cell renal cell carcinoma (ccRCC) comprising approximately 70% of all cases. ccRCC remains therapeutically challenging, particularly in patients whose disease progresses after therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors. Prostate-specific membrane antigen (PSMA), expressed in the tumor neovasculature of ccRCC, offers a potential therapeutic target for radiopharmaceutical therapy with 177Lu-PSMA-617, a well-established therapy in the management of prostate cancer. Methods: This is a single-center, open-label, single-arm, phase 2 clinical trial designed to evaluate the safety and efficacy of 177Lu-PSMA-617 in patients with advanced PSMA-positive ccRCC. Eligible participants must have measurable disease, have received at least 1 immune checkpoint inhibitor and 1 tyrosine kinase inhibitor, and demonstrate PSMA-avid disease in the majority of lesions on baseline 68Ga-PSMA-11 PET/CT. Patients will receive up to 6 cycles of 177Lu-PSMA-617 every 6 wk. A 2-stage design is used: 9 patients will be enrolled in stage 1, with trial continuation dependent on at least 1 objective response. If criteria are met, 15 additional patients will be enrolled, for a total of 24. The primary endpoint is the objective response rate in accordance with RECIST 1.1. Secondary endpoints include safety, progression-free survival, and overall survival. Exploratory objectives include the correlation of imaging biomarkers, circulating cell-free DNA, and genomic alterations with clinical outcomes. Conclusion: This prospective trial aims to evaluate the safety and preliminary efficacy of 177Lu-PSMA-617 in patients with advanced PSMA-positive ccRCC. The results of this study may support the clinical development of PSMA-targeted radiopharmaceutical therapy as a novel treatment option for patients whose disease has progressed after standard systemic therapies.
引用
- Hazut Krauthammer S, Xie W, LaBrecque N, et al. LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC. J Nucl Med. 2026. PMID: 41545068. doi:10.2967/jnumed.125.271273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。